GHK-Cu Was Discovered in 1973: A Short History of the Copper Peptide

In brief: GHK-Cu, the copper-binding tripeptide now common in serums, was not discovered by a skincare brand. It was identified in 1973 by biochemist Loren Pickart, who noticed differences between the plasma of younger and older adults. The fifty-plus years since have produced a slow, mostly academic research trail — small studies, in vitro work, and animal models — long before "copper peptide" became a search term.

Who discovered GHK-Cu?

GHK-Cu was discovered by biochemist Loren Pickart in 1973. Pickart was investigating what changes in human blood plasma as people age, and isolated a small tripeptide — glycyl-L-histidyl-L-lysine, or GHK — that behaved differently in samples from younger versus older donors. The peptide's defining trait was its strong affinity for copper ions, forming the complex now known as GHK-Cu.

This was laboratory biochemistry, not cosmetic science. Pickart's early work sat in academic journals focused on plasma proteins and tissue biology, years before "peptide" appeared on an ingredient label. For context on the molecule itself, see our GHK-Cu explainer.

Why plasma, and why aging?

Pickart's original interest was descriptive: he wanted to understand measurable differences in plasma composition across age groups. GHK levels were observed to be higher in younger plasma and lower in older plasma — an association that has been cited widely in the decades since, though it describes a correlation observed in blood, not a guarantee of what happens on skin when a peptide is applied topically.

Why does copper matter to the peptide?

Copper matters because GHK binds it so readily that the two are typically discussed as a single unit, GHK-Cu, rather than as a peptide with an optional add-on. The tripeptide's structure — three specific amino acids in sequence — creates a binding site well-suited to copper ions, and copper is a trace mineral already involved in numerous normal biological processes in skin and connective tissue.

This is part of why GHK-Cu is treated differently from copper alone or peptides alone in formulation circles: the complex itself is the subject of study, not its individual components in isolation. Elivae Bleu is built around this specific complex, at 1% concentration, in a fragrance-free base.

What has GHK-Cu been studied for since?

Since the 1970s, GHK-Cu has shown up in a wide range of research contexts, most of it academic rather than consumer-facing:

• Early tissue and wound-model research exploring how the peptide behaved in biological repair processes
• Skin-conditioning research as cosmetic chemists began formulating with copper peptides from the 1990s onward
• In vitro (cell culture) studies looking at how skin cells respond to GHK-Cu exposure
• Animal-model studies examining topical and systemic effects
• A smaller number of human studies measuring visible skin appearance outcomes

Cosmetic use of copper peptides grew steadily from the 1990s forward, well before the ingredient had any social media presence. That slow adoption curve is part of the story: formulators were experimenting with GHK-Cu in skin-conditioning products for roughly three decades before it became a widely recognized name.

How strong is the evidence, honestly?

The evidence is real but modest in scope, and it deserves a plain description rather than a marketing gloss. Most published research on GHK-Cu falls into a few honest categories: small human studies, in vitro cell studies, and animal models. Large, long-term, placebo-controlled human trials — the standard many people assume exists behind every popular ingredient — are not the norm for this peptide, nor for most cosmetic actives outside a handful of heavily studied ingredients.

That distinction matters for how any brand, including ours, is allowed to talk about it. Cosmetic products can describe effects on the appearance of skin. They cannot claim to change skin's underlying structure or function the way a drug would, because that is not what the available evidence supports for a topical cosmetic formula. Read more about what the research base does and doesn't show in what copper peptides do.

In short: decades of research exist, the mechanism is well characterized at a biochemical level, and interest in the compound has only grown — but "well-studied" is not the same as "definitively proven" for every appearance claim circulating online.

Why does a 50-year research history matter for a serum?

A fifty-year research history matters because it runs opposite to how most trending skincare ingredients arrive. Many actives go viral first and get studied later, if at all. GHK-Cu ran that sequence in reverse: it was identified in a lab in 1973, studied quietly across tissue biology, wound models, and cosmetic chemistry for decades, and only in recent years has it become a recognizable name outside research and formulation circles.

That timeline doesn't make GHK-Cu a miracle ingredient, and we won't claim it is one. It does mean the peptide has been sitting in the scientific literature, available for scrutiny, for longer than most of the actives currently competing for attention on social feeds. Elivae Bleu was formulated around that track record — 1% GHK-Cu, fragrance-free, nothing added to chase a trend — rather than around a discovery made the same year as its launch.

A quick timeline

This article is for general informational purposes and reflects the current, limited body of published research on GHK-Cu. It is not medical advice, and nothing here should be read as a claim that any product treats, cures, or prevents a medical condition. Individual skin responses vary.